Alcoholism & Drug Abuse Weekly最新文献

In February of 2017, when President-Elect Donald Trump was just into his first month in office, he proposed eliminating the Office of National Drug Control Policy. We covered this story in depth (see ADAW https://onlinelibrary.wiley.com/doi/10.1002/adaw.30864), and one former federal employee told us at the time: “Elections have consequences. Fundamentally, it's a Trump administration now.” It's true again, but this time, addiction treatment and prevention groups are better organized. The message is not one of gloom and doom: it is one of how to show that your programs have impact, a different former federal employee – who was with the government for almost four decades and whose boss changed with every new administration (and who survived every change) – told ADAW last week.

The International Nurses Society on Addiction Annual Educational Conference will be held March 11-14, 2025 in Disney Springs, Florida. For more information, go to https://www.intnsa.org/conference/

The conservative proposal which the Trump Administration is reportedly considering adopting, Project 2025, contains some of the following recommendations.

Last week the Pennsylvania Department of Drug and Alcohol Programs (DDAP) announced the availability of $2 million in funding to implement community-based prevention services throughout the state to prevent opioid use disorder (OUD). Funding for these grants is provided from the Mallinckrodt Opioid Settlement, which was the result of a multistate investigation spearheaded by then-Attorney General Josh Shapiro that led to billions in settlement agreements with opioid manufacturers and distributors. Shapiro is now governor.

National Institute on Drug Abuse director Nora Volkow, M.D. published a blog last week calling for community involvement in addiction science, and this means “[i]ncluding people with experience of substance use and addiction in the scientific workforce — and making sure they feel safe and recognized as valuable members of the research team…” Their perspectives, she wrote, “are invaluable in making sure that the right research questions are asked.” For the blog, go to https://nida.nih.gov/about-nida/noras-blog/2024/11/improving-community-engagement-in-addiction-science

“The next Administration must reaffirm a commitment to preventing drug use before it starts, providing treatment that leads to long-term recovery, and reducing the availability of illicit drugs in the United States.” This language appears on page 94 of the Project 2025 plan.

A year ago, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) formalized its office advancing the principles of diversity, equity, inclusion and accessibility (DEIA) both internally and in its scientific programs.

Amid the speculations that another Trump presidency will bring anti-science, anti-medicine policies, we looked back at the previous Trump administration. There was some of this, especially related to COVID. The federal workforce, especially at the Substance Abuse and Mental Health Services Administration, was decimated. It took more than a couple years to set things straight again. But the people in the trenches – the treatment programs, the street outreach workers, the clinicians who dedicate their lives to helping people with substance use disorders – were not affected by what happened in elections. They kept working to help patients and all who needed help. And they will still be there.

Results of two newly published studies suggest that any warnings pregnant women might be receiving about the health risks of marijuana use are being drowned out by assurances that smoking marijuana can relieve early pregnancy symptoms such as morning sickness.

A cohort study of 11,868 adolescents found that those who used cannabis at any point reported a greater number of psychosis symptoms, and more distress from those symptoms, compared to teens who never used cannabis. This study, “Psychosis Spectrum Symptoms Before and After Adolescent Cannabis Use Initiation,” published last week in JAMA Psychiatry, sought to answer the question of whether the cannabis use is an effort to self-medicate underlying psychosis, or contributes to increased vulnerability to psychosis. Findings were consistent with the self-medication hypothesis. The researchers concluded that it is important to account for both shared vulnerability, and self-medication effects, when modeling cannabis-psychosis risk associations. The study used data from 5 waves across 4 years of followup from the Adolescent Brain Cognitive Development (ABCD) Study.